Jeremy L. Ramdial, M.D.

Peer-Reviewed Articles

1. Ciurea SO, Kongtim P, Srour S, Saini N, Im J, Ramdial J, Khouri I, Anderlini P, Popat U, Hosing C, Champlin RE, Lee HJ, Fayad LE, Hagemeister FB, Bica AM, Lipan L, Craciun O, Jercan CG, Tanase A, Colita A. Can we cure refractory Hodgkin's lymphoma with transplantation?. Bone Marrow Transplant 56(1):1-4, 2021. e-Pub 2021. PMID: 32636464.
2. Evens AM, Danilov A, Jagadeesh D, Sperling A, Kim SH, Vaca R, Wei C, Rector D, Sundaram S, Reddy N, Lin Y, Farooq U, D'Angelo C, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Savani M, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein AK, Blum KA, Boughan KM, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Ramdial J, Maliske SM, Epperla N, Venugopal P, Feldman TA, Smith SD, Stadnik A, David KA, Naik S, Lossos IS, Lunning MA, Caimi P, Kamdar M, Palmisiano N, Bachanova V, Portell CA, Phillips T, Olszewski AJ, Alderuccio JP. Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers. Blood 137(3):374-386, 2021. e-Pub 2021. PMID: 32663292.
3. Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, Knape C, Aung FM, Scroggins J, Knopfelmacher A, Mulanovich V, Borjan J, Adachi J, Muthu M, Leung C, Medina MC, Champlin R, Olson A, Alousi A, Rezvani K, Shpall EJ. High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. Front Immunol 12:675679, 2021. e-Pub 2021. PMID: 33995420.
4. Kongtim P, Bittencourt M, Srour SA, Ramdial J, Rondon G, Chen J, Khouri I, Betul O, Popat U, Olson A, Bashir Q, Shpall EJ, Kebriaei P, Champlin RE, Ciurea SO. Haploidentical transplants for patients with graft failure after the first allograft. Am J Hematol 95(10):E267-E269, 2020. e-Pub 2020. PMID: 32602112.
5. Srour SA, Kongtim P, Rondon G, Chen J, Petropoulos D, Ramdial J, Popat U, Kebriaei P, Qazilbash M, Shpall EJ, Champlin RE, Ciurea SO. Haploidentical transplants for patients with relapse after the first allograft. Am J Hematol 95(10):1187-1192, 2020. e-Pub 2020. PMID: 32619033.
6. Torres A, Ramdial JL, Aguirre LE, Mahtani R, Vogel CL. Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients. Breast Cancer Res Treat 176(2):253-260, 2019. e-Pub 2019. PMID: 30900138.
7. Alderuccio JP, Zhao W, Desai A, Ramdial J, Gallastegui N, Kimble E, de la Fuente MI, Husnain M, Rosenblatt JD, Alencar AJ, Schatz JH, Moskowitz CH, Chapman JR, Vega F, Reis IM, Lossos IS. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. Am J Hematol 94(5):585-596, 2019. e-Pub 2019. PMID: 30784098.
8. Ramdial JL, Aguirre LE, Ali RA, Swords R, Goodman M. Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma. Case Rep Hematol 2019:4861673, 2019. e-Pub 2019. PMID: 31662918.
9. Alderuccio JP, Zhao W, Desai A, Gallastegui N, Ramdial J, Kimble E, de la Fuente MI, Rosenblatt JD, Chapman JR, Vega F, Reis IM, Lossos IS. Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. J Clin Oncol 36(34):3370-3380, 2018. e-Pub 2018. PMID: 30312133.
10. Hansra DM, McIntyre K, Ramdial J, Sacks S, Patrick CS, Cutler J, McIntyre B, Feister K, Miller M, Taylor AK, Farooq F, de Mayolo JA, Ahn E. Evaluation of How Integrative Oncology Services Are Valued between Hematology/Oncology Patients and Hematologists/Oncologists at a Tertiary Care Center. Evidence-Based Complementary and Alternative Medicine 2018(8081018), 2018. e-Pub 2018. PMID: 29849727.
11. Espejo AP, Ramdial JL, Wilky BA, Kerr DA, Trent JC. A nonrandom association of sarcoidosis in patients with gastrointestinal stromal tumor and other sarcomas. Rare Tumors 10:1-7, 2018. e-Pub 2018. PMID: 30038741.
12. Florou V, Ramdial J, Trent JC. GIST in Pregnancy: The Role of Circulating Tumor DNA to Define the Assessment of Risk of Rapid Progression and Response to Imatinib. AJHO 13(11):37-40, 2017. e-Pub 2017.
13. Mandel NS, Ramdial JL, Marcus EN. A second-degree burn after MRI. Cleve Clin J Med 84(5):348-349, 2017. e-Pub 2017. PMID: 28530901.
14. Catoe H, Ramdial J, Dejman A, Kupin W. Salmonella Abscess in a Failed Transplanted Kidney. J Infect Non Infect Dis 3:019, 2017. e-Pub 2017.
15. Patrick C, McIntyre K, Ramdial J, Joa S, Zaveri D, Hansra D. Novel ACLV1 mutation identified in late onset hereditary hemorrhagic. International J Otolaryngology and Head & Neck Surg 5(4):157-173, 2016. e-Pub 2016.
16. Oregel KZ, Ramdial J, Glück S. Nonsteroidal Anti-inflammatory Drug Induced Thrombotic Thrombocytopenic Purpura. Clin Med Insights Blood Disord 6:19-22, 2013. e-Pub 2013. PMID: 25512716.
17. Moore MJ, Hassan N, Gitzendanner MA, Bruenn RA, Croley M, Vandeventer A, Horn JW, Dhingra A, Brockington SF, Latvis M, Ramdial J, Alexandre R, Piedrahita A, Xi Z, Davis CC, Soltis PS, Soltis DE. Phylogenetic analysis of the plastid inverted repeat for 244 species: insights into deeper-level angiosperm relationships from a long, slowly evolving sequence region. International Journal of Plant Sciences 172(4):541-558, 2011. e-Pub 2011.
18. Brockington SF, Alexandre R, Ramdial J, Moore MJ, Crawley S, Dhingra A, Hilu K, Soltis DE, Soltis PS. Phylogeny of the Caryophyllales Sensu Lato: Revisiting Hypotheses on Pollination Biology and Perianth Differentiation in the Core Caryophyllales. International Journal of Plant Sciences 170(5):627-643, 2009. e-Pub 2009.
19. Brockington SF, Mavrodiev E, Ramdial J, Dhingra A, Soltis PS, Soltis DE. Keep the DNA rolling: multiple displacement amplification of archival plant DNA extracts. Taxon 57(3):944-E3, 2008. e-Pub 2008.

Review Articles

1. Ali R, Ramdial J, Algaze S, Beitinjaneh A. The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease. Biomedicines 5(4), 2017. e-Pub 2017. PMID: 29186076.

Abstracts

1. Nelson BE, Ramdial J, Bashir Q, Saini NY, Hosing C, Popat UR, Delgado R, Lee HC, Kaufman G, Orlowski RZ, Champlin RE, Qazilbash MH, Srour SA. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 28(3):S414-S415, 2023. e-Pub 2023.
2. Kawedia JD, Liu X, Ramdial J, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini NY, Kebriaei P, Knape C, Gulbis AM, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Creatinine Clearance Is Associated with Propylene Glycol-Free Melphalan (Evomela) Pharmacokinetics and Gastrointestinal Toxicities in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 29(2):S438-S439, 2023. e-Pub 2023.
3. Popat UR, Saliba RM, Mehta RS, Alousi AM, Al-trash G, Bashir Q, Hosing CM, Gulbis A, Im JS, Kebriaei P, Khouri IF, Kawedia JD, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Shigle TL, Srour SA, Rezvani K, Qazilbash MH, Andersson BS, Shpall EJ, Champlin RE. Myeloablative Fractionated Busulfan Fludarabine and Thiotepa Regimen for Haploidentical Donor Transplantation. Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 29(2):S167, 2023. e-Pub 2023.
4. Nieto Y, Yang Z, Valdez BC, Kundu S, Bassett R, Barnett M, Bashir Q, Ramdial J, Saini NY, Srour SA, Im JS, Kebriaei P, Popat UR, Gulbis AM, Cool R, Shigle TL, Wallis WD, Yeh J, Delgado R, Qureshi S, Lee HC, Manasanch E, Orlowski RZ, Thomas SK, Shpall EJ, Andersson BJ, Qazilbash MH. Safety and Efficacy of a New High-Dose Chemotherapy (HDC) Regimen of Panobinostat (Pano), Gemcitabine (Gem), Busulfan (Bu) and Melphalan (Mel) (Pano/GBM) with Autologous Stem Cell Transplant (ASCT) for Patients (pts) with High-Risk (HR) or Refractory/Relapsed (R/R) Myeloma (MM) – Matched Pair Comparisons with a Concurrent Control Cohort. Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 29(2):S31-S32, 2023. e-Pub 2023.
5. Shi D, Hosing C, Khouri IF, Saengboon S, Saini NY, Ramdial JL, Akin S, Bashir Q, Steiner R, Dabaja B, Pnnix C, Ahmed S, Alousi AM, Anderlini P, Kebriaei P, Qazilbash MH, Popat UR, Shpall EJ, Champlin RE, Nieto Y, Srour SA. Long-Term Outcomes after Autologous Stem Cell Transplant (ASCT) for Primary Central Nervous System Lymphoma (PCNSL). Transplantation & Cellular Therapy 2023 ASTCT Annual Meeti 29(2):S383, 2023. e-Pub 2023.
6. Saengboon S, Khouri IF, Hosing C, Ramdial JL, Saini NY, Akin S, Shi D, Steiner R, Malpica L, Ahmed S, Westin JR, Dabaja B, Wu SY, Alousi AM, Kebriaei P, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Nieto Y, Srour SA. Timing of Autologous Stem Cell Transplantation (ASCT) in Patients with Primary Central Nervous System Lymphoma (PCNSL). Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 29(2):S385-S386, 2023. e-Pub 2023.
7. Marinos A, Ramdial JL, Saliba RM, Khawaja F, Alousi AM, Rondon G, Chen J, Ledesma C, Chemaly RF, Champlin RE, Marin D, Daher M, Rezvani K, Shpall EJ. Long-Term Follow-up Outcomes of Patients That Underwent Allogeneic or Autologous Hematopoietic Transplant Shortly after a COVID-19 Infection. Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 29(2):S339-S340, 2023. e-Pub 2023.
8. Popat UR, Saliba RM, Mehta RS, Alousi AM, Al-Atrash G, Bashir Q, Chen J, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri IF, Kawedia JD, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Rezvani K, Qazilbash MH, Kantarjian H, Andersson BS, Champlin RE, Shpall EJ. Myeloablative Fractionated Busulfan Regimens in Matched Donor Transplantation. Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 29(2):S164-S165, 2023. e-Pub 2023.
9. Moustafa MA, Ramdial JL, Tsalatsani A, Khimani F, Dholaria B, Bojanini L, Zain J, Nennani NN, Braunstein Z, Brammer JE, Beitinjaneh A, Weng WK, Kumar A, Kharfan-Dabaj MA, Murthy HS, Ahmed S. Outcomes of Hematopoietic Cell Transplantation for Hepatosplenic T-Cell Lymphoma: A US Multicenter Collaborative Study. Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 29(2):S377, 2023. e-Pub 2023.
10. Chan KH, Ramdial JL, Hosing C, Srour SA, Alousi AM, Kebriaei P, Popat UR, Qazailbash MH, Ahmed S, Iyer SP, Lee HJ, Nair R, Steiner R, Strati P, Dabaja B, Fang P, Gunther JR, Pinnix C, We, SY, Cuglievan B, Mahadeo KM, Champlin RE, Shpall EJ, Nieto Y. Outcome of Patients with Classical Hodgkin Lymphoma (cHL) Relapsing after an Autologous Stem-Cell Transplant (ASCT). Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 29(2):S382, 2023. e-Pub 2023.
11. Carmona SN, Saengboon S, Bashir Q, Al-Atrash G, Cox N, Borthakur G, Vickers MR, Ramdial J, Kebriaei P, Popat, UR, Qazilbash MH, Shpall EJ, Champlin, RE, Srour SA. Impact of Smoking on Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation. Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 29(2):S147-S148, 2023. e-Pub 2023.
12. Pasvolsky O, Bassett R, Chanem S, Cuglievan B, Priti T, Hosing C, Srour S, Ramdial JL, Mahadeo KM, Khazal SJ, Petropoulos D, Popat UR, Qazilbash MH, Kebriaei P, Champlin RE, Shpall EJ, Nieto Y. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing First Autologous Hematopoietic Stem Cell Transplant. Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 29(2):S378-S379, 2023. e-Pub 2023.
13. Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Gender on Outcomes of Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant. Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 29(2):S404-S406, 2023. e-Pub 2023.
14. Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Lee HC, Patel KK, KLebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Single-Agent Lenalidomide Maintenance after Upfront Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma: The MD Anderson Cancer Center Experience. Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 29(2):S398-S399, 2023. e-Pub 2023.
15. Khawaja F, Sassine J, Handley G, Prakash R, Angelildakis G, Ahmed S, Ramdial JL, Nieto Y, Rondon G, Ariza-Heredia EJ, Spallone A, Iyer SP, Chemaly RF. Human Herpes Virus 6 Dnaemia within 1 Year of Chimeric Antigen Receptor T Cell Therapy. Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 29(2):S217-S218, 2023. e-Pub 2023.
16. Khawaja F, Sassine J, Handley G, Iyer SP, Ramdial J, Ahmed S, Nieto Y, Am S, Ariza-Heredia EJ, Chemaly RF. Herpesviruses Infections in CAR T Cell Recipients. Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 28(3):S381-S382, 2023. e-Pub 2023.
17. Srinivasan K, Khawaja F, Cantu S, Alousi AM, Ramdial J, Champlin RE, Shpall EJ, Frenzel E, Chemaly RF. Outcomes of Hospital-Associated Covid-19 in Hematopoietic Cell Transplant (HCT) Recipients: A Single Center Experience. Transplantation & Cellular Therapy 2023 ASTCT Annual Meeting 28(3):S331-S332, 2023. e-Pub 2023.
18. Pasvolsky O, Milton DR, Masood A, Shehzad S, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial JL, Nieto Y, Lee HC, Patel K, Kebriaei P, Thomas SK, Weber DM, Orlowsky RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience. Blood 64th ASH Annual Meeting 140(Supplement 1):10589–10591, 2022. e-Pub 2022.
19. Khawaja F, Prakash R, Sassine J, Handley G, VanWieren T, Angelidakis G, Iyer SP, Ramdial JL, Ahmed S, Nieto Y, Spallone A, Ariza-Heredia EJ, Chemaly R. Cytomegalovirus (CMV) Reactivation within in the First Year after Chimeric Antigen Receptor (CAR) T Cell Therapy: Experience from the First Two Years at a Major Cancer Center. Blood 64th ASH Annual Meeting 140(Supplement 1):7533–7535, 2022. e-Pub 2022.
20. Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour SA, Saini N, Lin P, Ramdial JL, Nieto Y, Tang G, Lee HC, Patel K, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Shpall EJ, Champlin RE, Lin P, Qazilbash MH. Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. Blood 64th ASH Annual Meeting 140(Supplement 1):284–286, 2022. e-Pub 2022.
21. Tang K, Khwaja R, Feng L, Strati P, Steiner RE, Nair R, Flowers CR, Saini N, Ramidal JL, Srour SA, Champlin RE, Rondon G, Torres J, Kebriaei P, Nastoupil LJ, Mistry H, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Ahmed S. Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy. Blood 64th ASH Annual Meeting 140(Supplement 1):4684–4685, 2022. e-Pub 2022.
22. Nieto Y, Banerjee PP, Kaur I, Griffin L, Ganesh C, Kerbauy L, Basar R, Kaplan M, Islam S, Esqueda D, Bassett R, Timmons M, Ramdial JL, Srour SA, Saini N, Hosing C, Ahmed S, Iyer SP, Alexis K, Emig M, Harstrick A, Shpall EJ, Rezvani K. Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma. Blood 64th ASH Annual Meeting 140(Supplement 1):415–416, 2022. e-Pub 2022.
23. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. Blood 64th ASH Annual Meeting 140(Supplement 1):10530–10531, 2022. e-Pub 2022.
24. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. Blood 64th ASH Annual Meeting 140(Supplement 1):7649–7650, 2022. e-Pub 2022.
25. Ramdial JL, Clemente-Sevilla L, Soebbing D, Dabaja BS, Thall PF, Alatrash G, Alousi AM, Mehta RS, Popat UR, Kebriaei P, Oran B, Rezvani K, Shpall EJ, Champlin RE. A Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies. Blood 64th ASH Annual Meeting 140(Supplement 1):7484–7485, 2022. e-Pub 2022.
26. Pasvolsky O, Saliba RM, Popat UR, Alousi AM, Mehta RS, Yeh J, Alatrash G, Masood A, Ramdial JL, Rondon G, Kebriaei P, Champlin RE, Shpall EJ, Oran B. Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 64th ASH Annual Meeting 140(Supplement 1):10550–10551, 2022. e-Pub 2022.
27. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT. Blood 64th ASH Annual Meeting 140(Supplement 1):4880–4881, 2022. e-Pub 2022.
28. Nair R, Ayers A, Nastoupil LJ, Gunther JR, Fayad L, Fowler NH, Miranda RN, Hagemeister FB, Lee HJ, Rodriguez MA, Steiner R, Strati P, Nieto Y, Ramdial J, Chihara D, Wang ML, Castillo LEM, Saini N, Jain P, Pinnix CC, Dabaja BS, Green MR, Flowers CR, Medeiros LJ, Marques-Piubelli ML, Vega F, Noorani M, Ahmed S, Westin J, Neelapu SS, Feng L, Iyer WP. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL. Blood 64th ASH Annual Meeting 140(Supplement 1):3800–3802, 2022. e-Pub 2022.
29. Nieto Y, Valdez BC, Thall PF, Ramdial JL, Srour SA, Hosing C, Saini N, Alousi AM, Qazilbash MH, Popat UR, Gulbis A, Shigle TL, Bassett R, Guillermo-Pacheco M, Ledesma C, Strati P, Ahmed S, Steiner R, Westin J, Nair R, Iyer SP, Champlin RE, Shpall EJ, Andersson BS. High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas. Blood 64th ASH Annual Meeting 140(Supplement_1):1183–1184, 2022. e-Pub 2022.
30. Ozcan G, UR| P, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Mehta RS, Ramdial JL, Rondon G, Shpall EJ, Champlin RE, Oran B. Transplant Outcomes for TP53 AML and MDS in a Contemporary Era. Blood 64th ASH Annual Meeting 140(Supplement 1):10620–10621, 2022. e-Pub 2022.
31. Chien KS, Peterson CB, Young E, Chihara D, Manasanch EE, Ramdial JL, Thompson PA. Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies. Blood 64th ASH Annual Meeting 140(Supplement 1):10938–10939, 2022. e-Pub 2022.
32. Kawedia JD, Liu X, Ramdial J, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini NY, Kebriaei P, Knape C, Gulbis AM, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Captisol-Enabled Melphalan (Evomela) Pharmacokinetics between Short and Long Infusion Arms in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S461-S462, 2022. e-Pub 2022.
33. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis AM, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S82-S83, 2022. e-Pub 2022.
34. Srinivasan K, Khawaja F, Cantu S, Alousi AM, Ramdial J, Champlin RE, Shpall EJ, Frenzel E, Chemaly RF. Outcomes of Hospital-Associated Covid-19 in Hematopoietic Cell Transplant (HCT) Recipients: A Single Center Experience. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S331–S332, 2022. e-Pub 2022.
35. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S83-S84, 2022. e-Pub 2022.
36. Gaballa M, Ma J, Tanner MR, Rauf M, Bashir Q, Srour SA, Saini NY, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman G, Manasanch E, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. KRD vs. VRD as Induction before Autologous Hematopoietic Progenitor Cell Transplantation for High-Risk Newly Diagnosed Multiple Myeloma. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S406-S407, 2022. e-Pub 2022.
37. Zurko JC, Ramdial J, Ahmed S, Szabo A, Iovino L, Shadman M, Acharya UH, Jacobson CA, Soiffer RJ, Wang TP, Komanduri KV, Iqbal M, Kharfan-Dabaja MA, Ayala E, Samara Y, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Nieto Y, Hamadani M, Herrera AF. Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory Large B-Cell Lymphoma after CAR T-Cell Therapy Failure. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S7-S9, 2022. e-Pub 2022.
38. Khawaja F, Sassine J, Handley G, Iyer S, Ramdial J, Ahmed S, Nieto Y, Spallone A, Ariza-Heredia EJ, Chemaly RF. Herpesviruses Infections in CAR T Cell Recipients. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S381–S382, 2022. e-Pub 2022.
39. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, VAldez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S293, 2022. e-Pub 2022.
40. Qazilbash MH, Bashir Q, Rauf M, Sui D, Srour SA, Popat UR, Saini NY, Hosing C, Ramdial J, Manasanch E, Lee HC, Kaufman G, Thomas S, Weber D, Becnel M, Tang G, Orlowski RZ, Guzman M, Champlin RE, Shpall EJ, Patel KK. Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hemaptopoietic Stem Cell Transplantation. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S404-S405, 2022. e-Pub 2022.
41. Srour SA, Saengboon S, Nelson BE, Ramdial J, Bashir Q, Vickers MR, Saini NY, Hosing C, Popat UR, Delgado R, Lee HC, Kaufamn G, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan Dose Intensity for Autologous Stem Cell Transplantation (ASCT) in AL Amyloidosis. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S426, 2022. e-Pub 2022.
42. Nelson BE, Ramdial J, Bashir Q, Saini NY, Hosing C, Popat UR, Delgado R, Lee HC, Kaufman G, Orlowski RZ, Champlin RE, Qazilbash MH, Srour SA. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S414-S415, 2022. e-Pub 2022.
43. Popat UR, Mehta RS, Thall P, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, ieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S78-S79, 2022. e-Pub 2022.
44. Mamlouk O, Strati P, Feng L, Sun R, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function. J Clin Oncol 2022 ASCO Annual Meeting 40(Suppl 16):abstr 7536, 2022. e-Pub 2022.
45. Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial JL, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide: Based maintenance after autologous hematopoietic stem cell transplant for patients with high-risk multiple myeloma. J Clin Oncol 2022 ASCO Annual Meeting 40(Suppl 16):abstr e20024, 2022. e-Pub 2022.
46. Popat U, Bassett R, Thall PF, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpalll EJ, Champlin RE, Andersson BS, Mehta RS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Blood 63rd ASH Annual Meeting 138(Supplement 1):556, 2021. e-Pub 2021.
47. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis A, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Blood 63rd ASH Annual Meeting 138(Supplement 1):2879, 2021. e-Pub 2021.
48. Nelson BE, Ramdial JL, Bashir Q, Saini N, Hosing C, Popat UR, Delgado R, Lee HC, Kaufman GP, Orlowski RZ, Champlin RE, Qazilbash MH, Srour SA. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. Blood 63rd ASH Annual Meeting 138(Supplement 1):482, 2021. e-Pub 2021.
49. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash M, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Blood 63rd ASH Annual Meeting 138(Supplement 1):1803, 2021. e-Pub 2021.
50. Ramdial JL, Saliba RM, Alousi AM, Rondon G, Chen J, Ledesma C, Shpall EJ, Chemaly R, Champlin RE. Allogeneic and Autologous Hematopoietic Transplants Can be Safely Performed after COVID-19 Infections. Blood 63rd ASH Annual Meeting 138(Supplement 1):2855, 2021. e-Pub 2021.
51. Al-Juhaishi T, Malek AE, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi A, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich V, Ahmed S. Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 63rd ASH Annual Meeting 138(Supplement 1):1779, 2021. e-Pub 2021.
52. Bashir Q, Thall PF, Sui D, Ramdial JL, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini N, Kebriaei P, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Patel KK, Orlowski RZ, Knape CG, Kawedia JD, Champlin RE, Shpall EJ, Liu X, Qazilbash MH. A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. Blood 63rd ASH Annual Meeting 138(Supplement 1):3941, 2021. e-Pub 2021.
53. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, NIeto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Blood 63rd ASH Annual Meeting 138(Supplement 1):1802, 2021. e-Pub 2021.
54. Nair R, Deen N, Ahmed S, Miranda RN, Fowler NH, Fayad L, Steiner RE, Hagemeister FB, Rodriguez MA, Lee HJ, Strati P, Malpica-Castillo L, Chihara D, Jain P, Gunther JR, Flowers CR, Medeiros J, Nieto Y, Ramdial JL, Neelapu SS, Nastoupil L, Green MR, Wang M, Vega F, Feng L, Iyer SP, Westin JR. Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. Blood 63rd ASH Annual Meeting 138(Supplement 1):1448, 2021. e-Pub 2021.
55. Gaballa MR, Ma J, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Lee HC, Patel KK, Kebriaei P, Thomas S, Webber D, Orlowski RZ, Sphall EJ, Champlin RE, Qazilbash MH. Long-Term Outcomes of Multiple Myeloma Patients Treated with VRD Induction, Autologous Hematopoietic Cell Transplantation with Melphalan 200 mg/m2 Conditioning, and Lenalidomide Maintenance. Transplant Cell Ther 2021 TCT Meetings Digital Experience 27(3, Supplement):S407-S408, 2021. e-Pub 2021.
56. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad L, Lee HJ, Iyer SP, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers C, Tummala S, Ramdial J, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):17-18, 2020. e-Pub 2020.
57. Saini N, Ma J, Timmons M, Alousi AM, Anderlini P, Andersson BS, Hosing C, Ramdial J, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Srour SA, Valdez BC, Dabaja BS, Pinnix CC, Gunther JR, Maadani F, Rondon G, Champlin RE, Nieto Y. High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC). Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):32-33, 2020. e-Pub 2020.
58. Nieto Y, Gruschkus SK, Jones RB, Valdez BC, Timmons M, Hosing C, Anderlini P, Kebriaei P, Popat UR, Qazilbash MH, Alousi AM, Srour SA, Saini N, Ramdial J, Im JS, Shpall EJ, Rezvani K, Gulbis A, Shigle TL, Mahadeo M, Khazal S, Khouri IF, Dabaja BS, Pinnix CC, Gunther JR, Lee H, Ahmed S, Steiner RE, Iyer SP, Nair R, Parmar S, Cuglievan B, Maadani F, Rondon G, Champlin RE, Andersson BS. Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):17-18, 2020. e-Pub 2020.
59. Ramdial J, Ma J, Milton DR, Delgado R, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Kaufman GP, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):6-7, 2020. e-Pub 2020.
60. Ramdial JL, Gaballa MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Weber DM, Kaufman GP, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):11-13, 2020. e-Pub 2020.
61. Gaballa MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini N, Ramdial J, Neito Y, Murphy R, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):14-15, 2020. e-Pub 2020.
62. Yalniz F, Saliba R, Greenbaum U, Ramdial J, Alousi A, Joseph J, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Shpall E, Mehta R, Qazilbash M, Popat U, Oran B, Champlin R, Kebriaei. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk Proceedings of the Society of Hematologic Oncology 2020 Annual Meeting 20(Supplement 1):S202, 2020. e-Pub 2020.
63. Husnain M, Komanduri K, Ramdial J, Lekakis LJ, Wang TP, Goodman M, Pereira DL, Beitinjaneh A, Carollo D, Ali R, Mohammed YN, Arshad J, Byrnes D, Saul EE, Aguirre LE, Jimenez AM. Pre-transplant molecular minimal residual disease (MMRD) is associated with inferior outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. J Clin Oncol 2020 ASCO Virtual Scientific Program 38(15_suppl):7547, 2020. e-Pub 2020.
64. Ramdial J, Ma J, Milton DR, Delgado R, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing CM, Popat UR, Lee, HC, Patel K, Yalniz FF, Champlin RE, Qazilbash MH. Peripheral Blood Stem Cell Mobilization for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Growth Factors Only Vs. Growth Factors + Chemotherapy. Biol Blood Marrow Transplant 2020 TCT Meetings of ASBMT & CIBMTR 26(3, Supplement):S286-S287, 2020. e-Pub 2020.
65. Qazilbash MH, Ramdial J, Bashir Q, Milton DR, Patel RD, Popat UR, Hosing CM, Kebriaei P, Alousi AM, Ciurea SO, Konopleva M, Champlin RE, Pemmaraju N. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for BPDCN. Biol Blood Marrow Transplant 2020 TCT Meetings of ASBMT & CIBMTR 26(3, Supplement):S106-S107, 2020. e-Pub 2020.
66. Yalniz F, Saliba RM, Yucel OK, Garcia-Manero G, Ramdial J, Popat U, Ciurea SO, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Hosing C, Marin D, Mehta R, Olson AL, Rezvani K, Shpall EJ, Rondon G, Champlin RE, Oran B. Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation. Blood 61st ASH Annual Meeting 134(Supplement 1):512, 2019. e-Pub 2019.
67. Evens AM, Danilov A, Jagadeesh D, Sperling A, Kim SH, Vaca R, Wei C, Rector D, Sundaram S, Reddy N, Lin Y, Farooq U, D'Angelo C, Bond DA, Berg S, Churnetski MC, godara A, Khan N, Choi YK, Yazdy M, rabinovich E, Varma G, Karmali R, Mian A, Ramdial J, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C Haverkos BM, Orellana-Noia VM, Kenkre V, Zayac A, Maliske SM, epperla N, Venugopal P, Feldman TA, Smith SD, Stadnik A, Lossos IS, David KA, naik S, Caimi P, Kamdar M, Portell CA, Olszewski AJ, Alderuccio JP. The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). Blood 61st ASH Annual Meeting 134(Supplement 1):397, 2019. e-Pub 2019.
68. Magistri M, Happ L, Ramdial J, Kunkalla K, Dubovy SR, Chapman JR, Vega F, Dave S, Lossos IS. Genetic Landscape of Ocular Adnexa Extranodal Marginal Zone Lymphoma. Blood 60th ASH Annual Meeting 132(Supplement 1):923, 2018. e-Pub 2018.
69. Alderuccio JP, Desai A, Crestani NG, Ramdial J, Kimble EL, De La Fuente MI, Chapman J, Vega F, Zhao W, Reis IM, Lossos IS. Outcomes in patients with marginal zone lymphomas undergoing transformation to high-grade lymphomas. J Clin Oncol 2018 ASCO Annual Meeting 36(15_suppl):7559, 2018. e-Pub 2018.
70. Torres AE, Vogel CL, Ramdial J, Mahtani RL, Sandoval-Leon A. Vinorelbine plus capecitabine in a heavily pretreated HER2 negative metastatic breast cancer patient population: MCEPASTEBIN. J Clin Oncol 2018 ASCO Annual Meeting 36(15_suppl):e13122, 2018. e-Pub 2018.
71. Hansra DM, Ramdial J, Ahn E, Perre A, Masar L, Brock A, Walters T, Randolph K, Alvarez RH. Expectations for survivorship care among hematology oncology and primary care providers. Journal of Clinical Oncology 2018 Cancer Survivorship Symposium 36(7_suppl):5, 2018. e-Pub 2018.
72. Freire APE, Ramdial J, Wilky BA, Kerr D, Trent JC. A nonrandom association of sarcoidosis in patients with gastrointestinal stromal tumor and other sarcomas. J Clin Oncol 2017 ASCO Annual Meeting 35(15_suppl):e22521, 2017. e-Pub 2017.
73. Desai A, Beitinjaneh A, Ramdial J, Ali R, Lekakis L, Pereira D, Kimble E, Florou V, Bravo G, Goodman M, Byrnes JJ, Jimenez AM, Saneeymehri S, Komanduri KV. Safety of High-Dose Melphalan (200 Mg/M2) as Conditioning for Autologous Stem Cell Transplantation for Myeloma in Elderly Patients. Biol Blood Marrow Transplant 2017 BMT Tandem Meetings 23(3, Supplement):S133-S134, 2017. e-Pub 2017.
74. Sheinberg D, Mohile N, Ramdial J, Faheem F, de Mayolo JA, Ahn E, Singal R, Hansra DM. Evaluation of hematology/oncology patient and physician opinions on medical office outpatient services in an ethnically diverse population. J Clin Oncol 2016 ASCO Annual Meeting 34(15_suppl):e18182, 2016. e-Pub 2016.
75. Hansra DM, Sacks S, Farooq F, Ramdial J, de Mayolo JA, Ahn E. Evaluation of hematology/oncology patient and physician expectations for integrative oncology at a tertiary care center. J Clin Oncol 2016 ASCO Annual Meeting 34(15_suppl):e18146, 2016. e-Pub 2016.
76. Lee C, Lieberman M, Faheem F, Ramdial J, Ahn E, de Mayolo JA, Singal R, Hansra DM. Evaluation of breast cancer patients’ and oncologists’ expectations for integrative oncology in an ethnically diverse population. J Clin Oncol 2016 ASCO Annual Meeting 34(15_suppl):e12028, 2016. e-Pub 2016.
77. Hansra D, Ramdial J, ruiz D, Mehta A, Ahn E, de Mayolo JA. PR118 Comparison of integrative care expectation between breast cancer patients and breast oncology physicians in an ethnically diverse population. The Breast Advanced Breast Cancer Third International Consensus Conference 24(Supplement 3):S62, 2015. e-Pub 2015.
78. Hansra DM, Ramdial J, Farooq F, de Mayolo JA, Ahn E, Mehta A. Evaluation of hematology/oncology patient and physician expectations for integrative oncology in an ethnically diverse population. 2015 ASCO Annual Meeting I 33(15_Suppl):6552, 2015. e-Pub 2015.
79. Hansra DM, Ramdial J, Farooq F, de Mayolo JA, Ahn E, Mehta A. Evaluation of hematology/oncology patient and physician expectations for integrative oncology in an ethnically diverse population. J Clin Oncol 2015 ASCO Annual Meeting 33(15_suppl):6552, 2015. e-Pub 2015.
80. Hansra D, Ramdial J, Martinez G, Farooq F, Torres A, Saravia D, Mehta A, Ahn E. Disparities between breast cancer patient and physician opinions for integrative oncology in an ethnically diverse population. 11th Annual International Conference of the Society for Integrative Oncology, 2014. e-Pub 2014.
81. Hansra D, Ramdial J, Martinez G, Farooq F, Torres A, Saravia D, Mehta A, Ahn E. Disparities Between Patient and Hematology/Oncology Physician Expectations for Integrative Oncology in an Ethnically Diverse Population. Blood 56th ASH Annual Meeting 124(21):2641, 2014. e-Pub 2014.
82. Njuguna W, Ramdial J, Hummer K, Bassil N, Dhingra A. Cytoplasmic Fingerprinting of Fragaria germplasm. 4th International Rosaceae Genomics Conference, 2008. e-Pub 2008.
83. Brockington SF, roolse A, Ramdial J, Dhingra A, Soltis PS, Soltis DE. Resolving poorly supported nodes in the order Caryophyllales: An ATOL Update. Plant Biology 2007 Botany & Plant Biology Joint Congress, 2007. e-Pub 2007.
84. Dhingra A, Ramdial JL, Peir G, Zhang X, Moore MJ, Jian S, Kahveci T, Soltis DE, Soltis PS, Folta KM. Computationally-assisted, high-throughput data mining for chloroplast genomics and phylogenetics. Plant Biology 2006 ASPB Conference, 2006. e-Pub 2006.
85. Dhingra A, Ramdial JL, Peir G, Colquhoun T, Zhang X, Moore MJ, Jian S, Kahveci T, Soltis P, Soltis D, Folta KM. ASAP- Breaking the comparative chloroplast genomics piñata. 17th Annual PMCB workshop, 2006. e-Pub 2006.
86. Dhingra A, Ramdial JL, Peir G, Soltis P, Soltis D, Folta KM. An evaluation of hypervariable plastid amplicons as phylogenetic markers. Plant & Animal Genome 2006 International Plant & Animal Genome Conference, 2006. e-Pub 2006.
87. Dhingra A, Ramdial JL, Peir G, Soltis P, Soltis D, Folta KM. An evaluation of hypervariable plastid amplicons as phylogenetic markers. Florida Genetics 2005, 2005. e-Pub 2005.

Book Chapters

1. Greenbaum U, Ramdial JL, Afrough A, Alsfeld LC, Ghanem S, Daher M, Olson A, Kebriaei P, Strati P, Steiner RE, Ahmed S, Tanner MR, Neelapu SS, Rezvani K, Shpall EJ. Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy. In: Manual of Hematopoietic Cell Transplantation and Cellular Therapies. Elsevier Inc, 509-524, 2024.
2. Ramdial JL, Jankowski ML, Nieto Y. Hematopoietic Cell Transplantation for Germ-Cell Tumors and Other Adult Solid Tumors. In: Manual of Hematopoietic Cell Transplantation and Cellular Therapies. Elsevier Inc, 395-402, 2024.
3. Sanchez-Petitto G, Szewczyk NA, Paul P, Ramdial JL. Transfusion Support During Hematopoietic Cell Transplantation. In: Manual of Hematopoietic Cell Transplantation and Cellular Therapies. Elsevier Inc, 67-81, 2024.
4. Petitto, GS, Szewczyk, NA, Paul, P, Ramdial, JL. Transfusion Support During Hematopoietic Cell Transplantation, 67-81, 2023.
5. Ramdial, JL, Jankowski, ML, Nieto, Y. Hematopoietic Cell Transplantation for Germ-Cell Tumors and Other Adult Solid Tumors, 395-402, 2023.
6. Greenbaum, U, Ramdial, JL, Afrough, A, Alsfeld, LC, Ghanem, S, Daher, M, Olson, AL, Kebriaei, P, Strati, P, Steiner, RE, Ahmed, S, Tanner, MR, Neelapu, SS, Rezvani, K, Shpall, E. Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy, 509-524, 2023.

Letters to the Editor

1. Florou V, Ramdial JL, Trent JC. Use of Tyrosine Kinase Inhibitors in Patients With GI Stromal Tumor Who Are Pregnant or Considering Pregnancy: Driver Mutations and Circulating Tumor DNA. J Clin Oncol 36: 2659-2660, 2018.

Web Publications

1. Ramdial JL. Understanding Allogeneic Stem Cell Transplants: What you Need to Know, 2024.